Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

The share of U.S. startup investment going to biotech companies has hit the lowest level in more than 20 years, as an ever-growing proportion of funding goes to AI upstarts in other sectors. We take a ...

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL ...

Despite facing significant federal hurdles in 2025, trade group leader sees reasons for cautious optimism in the life ...

Patients with primary progressive MS more commonly exhibited delays in overall disability progression following treatment with ocrelizumab vs placebo.

A research team at the National Institute of Technology Rourkela (NIT Rourkela), led by Prof A Thirugnanam from the ...

Dr Miché Desline Meyer, a trailblazing scientist from Mitchells Plain, shares her inspiring journey of perseverance through ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

The tissue engineering developer will address how her company’s breakthrough technology is transforming healthcare on October ...

Dr. Young holds a Ph.D. in chemistry from Princeton University, and received her BA and Masters in Chemistry from Wake Forest. In addition to serving on Terray's board, Dr. Young is an Advisor with GV ...

There is an exciting new biotechnology research project coming to two Louisiana Universities. DARPA, the central research and ...